Management of allergic rhinitis improves clinical outcomes of difficult-to-treat tic disorders or attention-deficit/hyperactivity disorders.

IF 6 Allergologie select Pub Date : 2023-10-23 eCollection Date: 2023-01-01 DOI:10.5414/ALX400588E
Rui-Li Yu, Jing Wang, Xue-Song Wang, Hong-Tian Wang, Xue-Yan Wang
{"title":"Management of allergic rhinitis improves clinical outcomes of difficult-to-treat tic disorders or attention-deficit/hyperactivity disorders.","authors":"Rui-Li Yu, Jing Wang, Xue-Song Wang, Hong-Tian Wang, Xue-Yan Wang","doi":"10.5414/ALX400588E","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This case series aimed to evaluate the effects of treatment for allergic rhinitis (AR) in AR-diagnosed children with previous diagnosis of tic disorders/attention-deficit/hyperactivity disorders (TD/ADHD) but unresponsive to behavioral or medical treatment.</p><p><strong>Materials and methods: </strong>Between July 2016 and June 2021, children diagnosed with AR in our hospital were enrolled. All were diagnosed with TD/ADHD refractory to behavioral or medical treatment. The demography and clinical information were collected from medical records. The outcomes were visual analogue scale (VAS) for AR severity, Yale Comprehensive Tic Severity Scale (YGTSS) for TD symptoms, and Attention-Deficit Hyperactivity Screening Scale (SNAP-IV) for ADHD symptoms.</p><p><strong>Results: </strong>A total of 27 children (18 boys, 9 girls) were included, with a mean age 7.4 ± 2.9 years (3 - 17 years). They had undergone behavioral or medical treatment of TD/ADHD for 3.6 ± 1.9 years but without significant improvement in TD/ADHD symptoms. After 2-6 months of systematic treatment for AR, VAS was decreased to 0.4 ± 0.1 from 0.8 ± 0.2, YGTSS to 3.5 ± 0.7 from 6.8 ± 1.4, and SNAP-IV to 0.4 ± 0.1 from 0.6 ± 0.2 (all p < 0.001). No recurrence of TD/ADHD symptoms was reported during a mean follow-up of 2.4 ± 1.1 years (0.5 - 5 years).</p><p><strong>Conclusion: </strong>AR treatment improves TD/ADHD outcomes in children with difficult-to-treat TD/ADHD. In TD/ADHD children who are unresponsive to behavioral or drug treatment and have AR-related symptoms, AR examination and treatment are recommended for better prognosis.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"7 ","pages":"191-197"},"PeriodicalIF":6.0000,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595139/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX400588E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: This case series aimed to evaluate the effects of treatment for allergic rhinitis (AR) in AR-diagnosed children with previous diagnosis of tic disorders/attention-deficit/hyperactivity disorders (TD/ADHD) but unresponsive to behavioral or medical treatment.

Materials and methods: Between July 2016 and June 2021, children diagnosed with AR in our hospital were enrolled. All were diagnosed with TD/ADHD refractory to behavioral or medical treatment. The demography and clinical information were collected from medical records. The outcomes were visual analogue scale (VAS) for AR severity, Yale Comprehensive Tic Severity Scale (YGTSS) for TD symptoms, and Attention-Deficit Hyperactivity Screening Scale (SNAP-IV) for ADHD symptoms.

Results: A total of 27 children (18 boys, 9 girls) were included, with a mean age 7.4 ± 2.9 years (3 - 17 years). They had undergone behavioral or medical treatment of TD/ADHD for 3.6 ± 1.9 years but without significant improvement in TD/ADHD symptoms. After 2-6 months of systematic treatment for AR, VAS was decreased to 0.4 ± 0.1 from 0.8 ± 0.2, YGTSS to 3.5 ± 0.7 from 6.8 ± 1.4, and SNAP-IV to 0.4 ± 0.1 from 0.6 ± 0.2 (all p < 0.001). No recurrence of TD/ADHD symptoms was reported during a mean follow-up of 2.4 ± 1.1 years (0.5 - 5 years).

Conclusion: AR treatment improves TD/ADHD outcomes in children with difficult-to-treat TD/ADHD. In TD/ADHD children who are unresponsive to behavioral or drug treatment and have AR-related symptoms, AR examination and treatment are recommended for better prognosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
过敏性鼻炎的治疗可改善难以治疗的抽动障碍或注意力缺陷/多动障碍的临床结果。
目的:本系列病例旨在评估变应性鼻炎(AR)治疗对AR诊断儿童的效果,这些儿童先前诊断为抽动障碍/注意力缺陷/多动障碍(TD/DADHD),但对行为或药物治疗没有反应。材料和方法:2016年7月至2021年6月,我们医院诊断为AR的儿童被纳入研究。所有患者均被诊断为行为或药物治疗难治的TD/DADHD。人口统计学和临床信息是从医疗记录中收集的。结果是AR严重程度的视觉模拟量表(VAS)、TD症状的Yale综合Tic严重程度量表(YGTSS)和ADHD症状的注意力缺陷多动障碍筛查量表(SNAP-IV)。结果:共纳入27名儿童(18名男孩,9名女孩),平均年龄7.4±2.9岁(3-17岁)。他们接受了3.6±1.9年的TD/DADHD行为或医学治疗,但TD/DADHd症状没有显著改善。AR系统治疗2-6个月后VAS从0.8±0.2降至0.4±0.1,YGTSS从6.8±1.4降至3.5±0.7,SNAP-IV从0.6±0.2降至0.4±0.1(均p结论:AR治疗改善了难以治疗的TD/DADHD儿童的TD/DVD结果。对于对行为或药物治疗无反应且有AR相关症状的TD/DVDD儿童,建议进行AR检查和治疗以获得更好的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Hymenoptera venom allergy: How negative testing after five years of immunotherapy informs treatment discontinuation. Therapy Allergen Ordinance (TAO): The final stretch. Ethical aspects of the application of artificial intelligence in allergology. Adrenaline nasal spray in emergency management: An initial expert opinion. AI - one size fits all?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1